News Releases & Research Results Identification of a novel biomarker for selecting liver cancer treatment - Clinical application for predicting malignancy and drug treatment effects -

The results of research conducted by Dr. Yuta Myojin, Assistant Professor Takahiro Kodama, and Professor Tetsuro Takehara (Gastroenterology), Graduate School of Medicine, Osaka University.

• Oncogene abnormalities, which differ with patients, are involved in the onset of liver cancer (intertumor heterogeneity). Based on the hypothesis that these differences influence the malignancy and drug treatment effects of cancer, a novel biomarker “ST6GAL1” was identified in a newly established mouse model.
• The results of this research should promote the utilization of a high serum level of ST6GAL1 as a biomarker for identifying highly malignant liver cancer and selecting optimal drugs in liver cancer therapy.

This project was conducted with the support of the Project for Cancer Research and Therapeutic Evolution by AMED.

The results were published in the American scientific journal Clinical Cancer Research on December 8.

Myojin Y., et al. ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma STEM CELLS Translational Medicine
DOI: 10.1158/1078-0432.CCR-20-3382